HCV: APASL issues HBV guidance for patients receiving DAA therapy

  • Kanda T & al.
  • Hepatol Int
  • 20 Sep 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The Asian Pacific Association for the Study of the Liver (APASL) has issued new guidelines for patients with current/prior HBV coinfection receiving HCV direct-acting antivirals (DAAs).

Supporting data

  • Experts reviewed data from 14 studies on HBV DNA reappearance and clinical reactivation among patients receiving DAA therapy.
  • Across 8 studies, viral DNA/clinical reactivation occurred in 41.4% (67/162) of patients positive for HBV surface antigen (HBsAg+) over a mean of 3 months posttreatment.
  • Among patients positive for anti-HBV core (anti-HBc) and/or anti-HBV surface (anti-HBs) antibodies at baseline, the 3-month rate was 0.91% (12/1317).

Recommendations for patients coinfected with HBV and HCV

  • HBsAg should be evaluated at baseline in HBV-endemic areas.
  • HBsAg+ patients with advanced fibrosis, cirrhosis, or prior hepatocellular carcinoma should receive preemptive treatment with nucleos(t)ide analogs (NAs).
  • In the absence of these conditions, HBsAg+ patients should receive preemptive NAs or close monitoring during treatment and for 24 weeks thereafter.
  • HBsAg-negative patients with anti-HBc/HBs antibodies should be tested for HCV RNA, HBsAg, and HBV DNA if liver function tests are abnormal during or after DAA treatment.
    • NAs should be used to treat HBV reactivation.
  • The above provides only an overview, and clinicians should consult the complete guidelines for details.
  • Funding: None.